Table 1 Summary of Patient–Tumor Cohort and Fluorescence In Situ Hybridization Immunohistochemical Results

Case No.	Age (y)/Sex	Diagnosis	Site	NF2	Merlin	DAL-1	DAL-1
1	15/F	E	Spinal	Polysomy	+	Polysomy	+
2	44/F	E	Spinal	Deleted	+	Polysomy	+
3	16/F	MPE	Spinal	Polysomy	+	Polysomy	+
4	41/F	E	Spinal	Normal	−	Polysomy	+
5	38/F	E	CMJ	Deleted	−	Normal	+
6	65/M	E	Spinal	Deleted	−	Polysomy	+
7	33/F	MPE	Spinal	Polysomy	+	Deleted	−
8	56/M	E	Spinal	Deleted	+	Deleted	−
9	25/F	MPE	Spinal	Normal	+	Polysomy	+
10	13/F	E	Spinal	Polysomy	−	Polysomy	+
11	53/M	E	Spinal	Normal	+	Polysomy	+
12	28/M	E	Spinal	Polysomy	+	Polysomy	+
13	40/M	MPE	Spinal	NI	+	NI	+
14	69/F	E	Spinal	Polysomy	+	Normal	+
15	44/F	MPE	Spinal	Deleted	−	Normal	+
16	1/M	E	Post. Fossa	Normal	+	Deleted	−
17	5/M	AE	Post. Fossa	Polysomy	+	Polysomy	+
18	9/F	AE	Cerebral	Polysomy	+	Polysomy	+
19	27/M	AE	Cerebral	NI	+	NI	−
20	44/M	E	Post. Fossa	Polysomy	+	Polysomy	+
21	9/M	AE	Post. Fossa	Polysomy	+	Deleted	−
22	22/M	E	Post. Fossa	Normal	+	Polysomy	+
23	18/M	E	Cerebral	Normal	+	Polysomy	+
24	2/M	E	Post. Fossa	Deleted	+	Deleted	+
25	7/M	AE	Post. Fossa	Normal	+	Deleted	−
26	2/M	AE	Post. Fossa	Polysomy	+	Polysomy	−
27	72/F	E	Post. Fossa	Polysomy	+	Polysomy	+

Dx, diagnosis; E, ependymoma; MPE, myxopapillary ependymoma; AE, anaplastic ependymoma; CMJ, cervicomedullary junction; Post. Fossa, posterior fossa; NI, noninformative.

Quick links

Search